Revival of Stem Cells in Addison's Study (RoSA)

Newcastle University

Status and phase

Completed

Phase 4

Conditions

Adrenal Failure

Treatments

Drug: depot tetracosactide

Study type

Interventional

Funder types

Other

Identifiers

NCT01371526

RoSAv1.2:04_10: R&D#5252

2009-018074-56 (EudraCT Number)

Details and patient eligibility

About

Autoimmune Addison's disease (AAD) is a rare and debilitating disease in which an autoimmune attack progressively destroys the adrenal cortex. Untreated it is universally fatal and treated people are absolutely dependent upon steroid medications lifelong, with a consequent excess in morbidity and mortality. A key feature of the adrenal cortex is that its cells are responsive to changes in circulating adrenocorticotrophic hormone (ACTH) concentration. This study aims to regenerate adrenocortical steroidogenic cell function in patients with established autoimmune Addison's disease (AAD) by stimulating proliferation and differentiation of their progenitor cells, the adrenocortical stem cells (ACSCs) (1,2). Using daily subcutaneous ACTH, administered according to two different regimens over 20 weeks, we will investigate whether regeneration of adrenal steroidogenic function through revival of ACSC activity is a realistic possibility.

Enrollment

13 patients

Sex

All

Ages

16 to 66 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Established autoimmune adrenal failure for >1yr age 16 to 65

Exclusion criteria

Significant cardio-respiratory, chronic renal or non-autoimmune liver disease; malignancy
Asthma, current infectious disease, recent live vaccination, acute psychosis, peptic ulcer disease
Pregnancy, breast feeding or plan for pregnancy within 9 months
Known non-autoimmune cause for adrenal failure (haemorrhage, adrenoleukodystrophy etc.)
Known hypersensitivity or allergy to Synacthen